Physician profile
Kathryn E Cameron
NPI 1962594572
$784.97
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2021: $250 · 2022: $371 · 2023: $45.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $45.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $45.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $278.91 | 2021-2023 | Ubrelvy |
| Glaxosmithkline, LLC. | $82.18 | 2019-2023 | Arexvy, Shingrix |
| Novo Nordisk INC | $48.75 | 2021 | |
| Allergan, INC. | $39.82 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.39 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.58 | 2022 | |
| Janssen Pharmaceuticals, INC | $35.56 | 2019-2021 | |
| Lilly USA, LLC | $33.63 | 2022 | |
| Amarin Pharma, INC. | $32.28 | 2019-2021 | |
| Abbott Laboratories | $32.23 | 2022 | |
| Sanofi Pasteur INC. | $31.81 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.54 | 2022 | |
| Daiichi Sankyo INC. | $16.19 | 2021 | |
| Eisai INC. | $15.45 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.36 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12.26 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Cameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.